• Autosomal recessive congenital ichthyoses (ARCI) are genetically driven skin disorders marked by varying levels of scaling and often accompanied by redness. Symptom severity differs among individuals due to mutations in different genes, and the condition significantly impacts patients’ quality of life.
• The rising number of ARCI cases can be attributed to several factors. Improved genetic testing and diagnostic techniques have led to better identification and classification of the disorder. Additionally, increased awareness, higher rates of consanguineous marriages in certain populations, and better survival of affected infants due to advances in neonatal care contribute to the apparent increase in prevalence.
• According to the secondary analysis, the estimated prevalence of ARCI varies from one case per 139,000 to 300,000 individuals.
• The rarity and clinical heterogeneity of ARCI often lead to delayed diagnosis and misclassification, particularly in regions with limited access to specialized dermatological and genetic services.

ARCI Epidemiology Forecast in the 7MM

DelveInsight's ‘ARCI – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the ARCI, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

ARCI Understanding and Diagnosis

ARCI Overview and Diagnosis

ARCI are a group of chronic, inherited skin disorders characterized by widespread scaling and varying levels of redness (erythema), typically presenting at birth or in early infancy. These conditions encompass multiple non syndromic ichthyosis subtypes, each with distinct clinical features and severity. Harlequin ichthyosis represents the most severe and potentially life-threatening form, while lamellar ichthyosis and congenital ichthyosiform erythroderma (CIE) are less severe yet still impactful. Additionally, intermediate phenotypes exist, presenting with variable scale size, texture, and degrees of erythema. ARCI is caused by mutations in various genes involved in skin barrier formation, including TGM1, ABCA12, ALOX12B, ALOXE3, NIPAL4, CYP4F22, PNPLA1, CERS3, LIPN, and SULT2B1. 

Diagnosing ARCI involves a thorough clinical evaluation, including history of neonatal features such as a collodion membrane, ectropion/eclabium, and signs of systemic complications. Physical examination focuses on scale characteristics, erythema, xerosis, alopecia, nail dystrophy, and joint deformities. Eye and growth assessments are also vital. A three-generation family history is reviewed, though absence of affected relatives does not rule out ARCI. Genetic diagnosis may involve gene-targeted panels or comprehensive genomic sequencing to identify causative mutations.

Further details are provided in the report.

ARCI Epidemiology

Key Findings from ARCI Epidemiological Analysis and Forecast 

• Based on a secondary analysis, the estimated prevalence of ARCI varies from one case per 139,000 to 300,000 individuals.
• In France, estimates suggest that moderate to severe types of ARCI affect 1–7 people per 100,000.
• As per secondary analysis, Mutations in eleven genes are associated with the development of ARCI out of which 32%–68% of cases develop due to germline mutations in the transglutaminase (TG) 1 gene, TGM1.
  

Total Diagnosed Prevalent Cases of ARCI in the 7MM in 2025

Scope of the Report

• The report covers a segment of key events, an executive summary, a descriptive overview of ARCI, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

ARCI Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report 
• 11-Year Forecast 

FAQs

• What are the disease risks, burdens, and unmet needs of ARCI? What will be the growth opportunities across the 7MM concerning the patient population with ARCI?
• What is the ARCI prevalence in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• What is the historical and forecasted ARCI patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on ARCI burden and disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• Clear methodology, validated assumptions, and data-driven rationale to assess the ARCI epidemiology analysis and patient population trends.